Table 1.
Baseline patient characteristics
| Characteristics | Pemetrexed + cyclophosphamide (n=30) | Pemetrexed (n=32) | P-values |
|---|---|---|---|
| Gender | 0.77 | ||
| Male | 26 | 28 | |
| Female | 4 | 4 | |
| Median age (years) | 56 (31-81) | 42 (32-52) | |
| ≥60 | 8 | 9 | 0.26 |
| Performance status | 0.94 | ||
| 0 | 5 (17%) | 5 (16%) | |
| 1 | 13 (43%) | 13 (41%) | |
| 2 | 12 (40%) | 14 (44%) | |
| Smoking status | 0.88 | ||
| Current or ex-smokers | 21 (70%) | 24 (75%) | |
| Nonsmokers | 9 (30%) | 8 (25%) | |
| Pathological subtype | 0.99 | ||
| Adenocarcinoma | 12 (40%) | 14 (44%) | |
| Squamous cell carcinoma | 10 (33%) | 12 (37%) | |
| Large-cell neuroendocrine carcinoma | 8 (27%) | 6 (19%) | |
| Stage at treatment | |||
| IIIB | 3 (10%) | 6 (19%) | |
| IV | 27 (90%) | 26 (81%) | |
| Metastatic sites | 0.59 | ||
| Lung to lung | 21 (70%) | 21 (66%) | |
| Pleura | 16 (54%) | 26 (81%) | |
| Brain | 2 (7%) | 4 (12%) | |
| ≥2 sites | 23 (77%) | 18 (56%) | |
| Treatment sequence | 0.32 | ||
| 3rd line | 13 (43%) | 18 (56%) | 0.57 |
| 2nd line | 12 (40%) | 21 (66%) | 0.80 |
Values are presented as number (%, rounded off).